Watch this physician panel to hear Drs @MReardon19 , @chrismeduri , and @azeemlatib discuss the design of the DurAVR™ transcatheter heart valve and the paradigm-shifting hemodynamic results from the US Early Feasibility Study (EFS): https://t.co/G20StDcEfW
Further evidence that DurAVR™ the first in class biomimetic valve built on the Adapt® tissue platform is showing exceptional results due to its novel valve design and superior tissue science whilst maintaining more predictable delivery with a novel BE platform #valvedesign
#PCRLV: @azeemlatib presents insights from the first in man implant of the DurAVR biomimetic TAVI valve (@AnterisTech). He reports that the device had a favourable safety profile, and “outstanding” haemodynamic performance
#PCRLV: @azeemlatib presents insights from the first in man implant of the DurAVR biomimetic TAVI valve (@AnterisTech). He reports that the device had a favourable safety profile, and “outstanding” haemodynamic performance
Last week Stephanie Sellers presented bench testing results from the novel DurAVR™ THV at #TCT2023. DurAVR demonstrated superior hemodynamic performance in Redo-TAVR procedures. Learn more about DurAVR here: https://t.co/qIicm0LAyu
#TAVR#TAVI#innovation#AnterisTech
Is this aortic flow normal?
Two papers will help to understand the pathophysiological aetiology better -
https://t.co/De5cOQVZdo
https://t.co/BQixK3jlqD
Aortic flow MATTERS. 💯
Great way to end a great week. Meeting with the V2V team to discuss our unique TEER device for mitral repair.Thanks to the Anteris team for all the work that culminated in a great #TCT for #AVR#movingtheconversationforward#proudtobeanteris
$AVR one of the unique distinguishing features of #DurAVR is the return of near perfect laminar flow. This impacts on valve durability, performance +. As > evidence emerges this will become a required expectation in valve performance. No other valve achieves this. #TAVR#TCT2023
Great week at TCT with incredible data being presented by Anteris demonstrating superior MPG's ,superior EOA's and superior DVI's to current therapies. A huge thanks to our team,Physicians and patients. We are moving the conversation forward ! #proudtobeanteris#DurAVR
It's been an exciting day of TAVR data at #TCT2023, with major updates on #TAVR studies! It's clear that valve performance matters. Tune in this afternoon for DurAVR™ THV US EFS discharge data -- moving the conversation forward with paradigm-shifting hemodynamic performance!
Standing room only! At #TCT2023, @chrismeduri presented the latest data from the DurAVR™ THV FIH Study. Remarkable hemodynamic results are holding steady at 6 months and 1 year post-op! More info: https://t.co/qIicm0M8o2
#TAVR#TAVI#clinicaltrial#innovation
DurAVR US EFS results presented @TCTMD by @azeemlatib today
In small annuli patients (mean 22.2):
✔️ safe, easy to use
✔️ no pacemakers
✔️ 93% no/trace, 7% mild PVL
🎯mean EOA 2.36
🎯MPG 7.8
🎯DVI 0.71
This groundbreaking, first biomimetic valve will change AS treatment
@AnterisTech@tavrkapadia@ClevelandClinic Thanks Dr Kapadia, Dr Krishnaswamy and Dr Puri and your fantastic team for completing 3 more patients. Thanks to the patients as well for participating, great results by a great team. #proudtobeanteris#DurAVR#TCT
$AVR Anteris Technologies improves US investor access with American Depository Receipt program https://t.co/lhxdBsPc6d @AnterisTech $DDF $AMEUF #AVR#DDF#AMEUF#ASX#ASXNews